Breaking News

Frontage Shanghai Acquires Wuhan Heyan Biomedical

Provides target based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Frontage Shanghai has acquired 70% equity interest in Wuhan Heyan Biomedical Technology Co., Ltd.   Heyan Biotech, located in Wuhan Optics Valley, national biotech industry base, provides for target based in vitro pharmacodynamic screening and early pharmacological pharmacodynamic evaluation services in early drug discovery. Technical capabilities include screening of drug targets, customized biological assay development and detection services.   Dr. Song Li, Chairman and CEO of Frontage, sa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters